sysVASC // EU Project

Project description:

Asymptomatic vascular damage accumulates for years before patients are identified and subjected to therapeutic measures. The limited knowledge on early vascular disease pathophysiology is reflected in the lack of therapeutic options. sysVASC aims to overcome this limitation by mounting a comprehensive systems medicine approach to elucidate pathological mechanisms, which will yield molecular targets for therapeutic intervention.
The consortium is based on established multidisciplinary European research networks, including specialists in pre-clinical and clinical research, omics technologies, and systems biology from research intensive SMEs and academia; partners synergistically provide access to an extensive number of selected population-based cohorts and associated datasets, cutting edge modeling and simulation methods, and established cardiovascular disease (CVD) animal models and patient cohorts. The coordinated application of these tools and know-how will identify pathophysiological mechanisms and key molecules responsible for onset and progression of CVD and validate their potential to serve as molecular targets for therapeutic intervention. To this end, the consortium will also use unique resources to evaluate molecular homology between the available model systems and human disease, which will yield reliable essential preclinical research tools to explore proof of concepts for therapeutic intervention studies and ultimately translate relevant results into novel therapeutic approaches.
Collectively, sysVASC will identify and validate novel biology-driven key molecular targets for CVD treatment. Major scientific, societal and economic impact is expected including, but not limited to, providing a valuable resource to further CVD research, and enhance competitiveness of participating SMEs and European health industry in general by translating knowledge into “innovative services” in therapeutic target and drug research.

Photo

Quick overview:

Programme: FP7 – HEALTH
Project Reference: 603288
Coordinator: Medical University Graz, Austria
Status: Execution
Start: 01.02.2014
End: 31.01.2018
Total Cost: EUR 8,334,864
EU contribution: EUR 5,976,41

PROJECT WEBSITE CORDIS LINK

biolution contribution:

Proposal preparation: Content, Administration
Implementation: Dissemination
Photo
Photo

Partners / Collaborations

Baker Idi Heart & Diabetes Institute, AU
Biocrates Life Sciences, AT
biolution GmbH, AT
Medical University of Graz, AT
University of British Columbia, CA
Inserm Toulouse, FR
Mosaiques Diagnostics, DE
The German Research Center for Environmental Health, DE
University of Tübingen, DE
Biomedical Research Foundation, GR
University College Dublin, IE
ServiceXS BV, NL
Swiss Institute for Bioinformatics, CH
Eagle Genomics, UK
University of Manchester, UK
University of Glasgow, UK
University of Plymouth, UK
baker_idi_logo
biocrates_logo1
biolution_logo
med_uni_graz_logo
ubc_logo
inserm_logo
mosaiques_logo
hzm_logo
eberhardtueringen_logo
brfaa_logo
ucd_logo
service_xs_logo
sib_logo
eagle_logo
manchster_logo
glasgow_logo
plymouth_logo
Cardiovascular Communication Consulting EU Projects FP7

Related items: